东瑞制药(02348.HK)中期股东应占溢利减少9.5%至1.5亿元中期息0.015港元
格隆汇8月26日丨东瑞制药(02348.HK)公布，截至2019年6月30日止6个月，公司收入4.9亿元人民币（下同），同比减少1.2%；毛利2.95亿元，同比减少5.6%；公司拥有人应占溢利1.5亿元，同比减少9.5%；每股盈利0.09485元，每股中期股息0.015港元。
收入与利润的减少，主要是本集团专科药物恩替卡韦销售有所下降，同时，亦由于该集团头孢菌素粉针剂销售额与2018年同期比较有所下降所致。
期间毛利额约人民币295,075,000元，较去年同期减少人民币17,597,000元。毛利率为60.1%，较去年同期的62.9%下降了2.8个百分点。主要是雷易得销售下降影响。
在竞争激烈的市场环境下，该集团治疗高血压的"安"系列产品的销售额与2018年度同期相比增长12.0%；抗过敏药物西可韦、西可新同比增长14.5%；继续为该集团盈利作出重大贡献。但雷易得(恩替卡韦分散片)受香港落标和4+7集采的影响，于回顾期内销售额比上年同期降幅较大，下跌47.4%。头孢菌素中间体及原料药由于该集团不断提高产品品质，降低生产成本，中间体及原料药产品竞争能力较大提高。销售额增长7.3%，分类业绩略有盈利。
该集团自2019年5月7日收购兴安药业有限公司以来，在销售团队的努力下，其降血脂类药物（阿托伐他汀钙片）迅速切入市场，同时带动其他原有兴安药业产品销售。于2019年6月30日兴安药业产品已在全国27个省市自治区销售。
期内，该集团营销管理人员紧密检查各项业务计划成效，因应市场急促变化，适当调整该集团产品营销思路和营销策略并加强资源配置，积极开拓空白市场，深耕现有市场，开拓新产品市场以确保该集团销售额持续稳定的状况，消除4+7集采带来的影响。
此外，该集团已于2019年6月取得盐酸左西替利嗪片一致性评价注册补充批件，此外，截至2019年6月30日止，该集团进行质量一致性研究品种18个。其中3个品种已向国家药品监督管理局药品审评中心进行一致性评价申请，另有2个品种正在进行生物等效性（BE）临床研究，13个品种在做药学研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
